Ubs Oconnor LLC Blueprint Medicines Corp Transaction History

Ubs Oconnor LLC

$2.23 Billion
Q2 2025

A detailed history of Ubs Oconnor LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ubs Oconnor LLC holds 1,713,587 shares of BPMC stock, worth $222 Million. This represents 9.85% of its overall portfolio holdings.

Number of Shares

1,713,587

Holding current value

$222 Million

% of portfolio

9.85%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$79.22 - $128.4 $135 Million - $218 Million	1,698,722 Added 11427.66%	1,713,587 $220 Million
Q1 2025 May 15, 2025	SELL	$86.69 - $115.63 $456,682 - $609,138	-5,268 Reduced 26.17%	14,865 $1.32 Million
Q4 2024 Feb 14, 2025	SELL	$82.48 - $101.39 $174,857 - $214,946	-2,120 Reduced 9.53%	20,133 $1.76 Million
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $497,030 - $712,155	5,910 Added 36.16%	22,253 $2.06 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $141,143 - $180,248	-1,657 Reduced 9.21%	16,343 $1.76 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $658,530 - $898,110	9,000 Added 100.0%	18,000 $1.71 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $1.76 Million - $3.71 Million	-39,984 Reduced 81.63%	9,000 $830,000
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $56,280 - $79,200	1,200 Added 2.51%	48,984 $2.46 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $2.02 Million - $3.17 Million	47,784 New	47,784 $3.02 Billion
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $289,597 - $381,350	7,627 Added 18.33%	49,233 $2.21 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $1.71 Million - $2.77 Million	41,606 New	41,606 $0
Q2 2022 Aug 12, 2022	BUY	$45.23 - $70.15 $198,559 - $307,958	4,390 Added 27.44%	20,390 $1.03 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $865,600 - $1.76 Million	16,000 New	16,000 $1.02 Million

Others Institutions Holding BPMC

# of Institutions

400

Shares Held

67.3M

Call Options Held

973K

Put Options Held

1.54M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account